PAC Pet

PAC Pet is a veterinary biotechnology company focused on developing innovative cancer treatments for companion animals, specifically dogs. The company's lead therapeutic candidate is PAC-1, a small molecule that targets and activates procaspase-3, an enzyme that is often overexpressed in cancer cells and responsible for triggering programmed cell death (apoptosis). By selectively inducing apoptosis in malignant cells, PAC-1 offers a novel mechanism of action compared to traditional chemotherapy. PAC Pet conducts clinical trials in pet dogs with naturally occurring cancers, such as lymphoma and osteosarcoma, to evaluate the safety and efficacy of its treatments while providing advanced care options for pet owners.